Alnylam’s Blood Pressure Drug: Not Exactly Heartwarming Yet
Alnylam just dropped data from their so-called 'investigational therapy' that was supposed to be the Tesla of blood pressure meds but ended up more like a tricycle. Their Phase 2 trial, aka the 'Thrill of Mediocrity,' didn't significantly lower blood pressure. Yet, in a plot twist worthy of a soap opera reboot, the company decided to plunge forward into a late-stage study—because why quit when you can pretend progress? No dollar amounts or dates were shared, but one thing’s clear: Alnylam is writing a new chapter in the 'Lower Your Expectations' saga. If clinical trials were auditions, this one got a polite nod to keep trying.
Share the Story
(1 of 3)Alnylam’s blood pressure med didn’t budge the dial, but hey, let’s double down on hope and move to late stage—because who doesn’t love trying the same thing harder until it magically works?
Who knew the secret to clinical success is a solid game of pretend? Alnylam’s drug flopped Phase 2 yet gets a free pass to late stage like it’s the kid who flunked math but still makes varsity cheerleading.
'Significantly lowers blood pressure' took a sick day, but Alnylam’s optimism shows up on time and boots—time to double down on science’s version of 'hold my beer.'
Source: Statnews | Published: 8/30/2025 | Author: Elaine Chen
More Articles in Health
Motorola Razr Flip Phones Finally Told They’re Secure Enough for 2027
KPMG’s Consulting Business Dies Dramatically While Staff Take a Hike
America Tries Staying Cool While Secretly Preparing For Wattocalypse
90-Year-Old Dad Outsources Bathing to Jovial Nigerian and Ghanaian Carers
Woman Ages Backwards in Online Writing Class, Still Loses to 21-Year-Old
Billionaire’s Daughter’s Brain Hemorrhage Detected Belatedly By $299 Ring
Dietitians Unite to Demand We Eat More Beans, Save Humanity from Boredom
Mark Cuban Declares AI Too Empathetic to Replace Doctors, Only Bullshit Jobs Fear
